Accuray announces prostate cancer data showing benefits of SBRT treatment

Accuray announced that data from the PACE-A trial indicates that stereotactic body radiation therapy, or SBRT, in comparison to surgery, better preserves urinary continence and sexual function in men with localized prostate cancer. An analysis of patient reported outcomes found that at two years, significantly fewer patients – 4.5% – treated with SBRT reported needing to use urinary pads, which manage urinary incontinence, compared with surgery – 47% -. Patients treated with SBRT also reported better sexual function after two years than those treated with surgery. SBRT is a highly targeted form of external beam radiation therapy that involves the delivery of very high doses of radiation over a small number of treatment sessions. Accuray’s CyberKnife System is designed to deliver SBRT.